Cat. No.: HY-N2122

Neoisoliquiritin

(Synonyms: Neoisoliquiritigenin)

Customer Review

Based on 1 Customer Validation

Neoisoliquiritin (Neoisoliquiritigenin) is an androgen receptor (AR) inhibitor. Neoisoliquiritin inhibits the ATPase activity of GRP78. Neoisoliquiritin induces G₀/G₁ cell cycle arrest and inhibits proliferation in cancer cells, while it also induces cell apoptosis (apoptosis). Neoisoliquiritin suppresses tumor growth in mouse models of prostate cancer and breast cancer. Neoisoliquiritin can be used in studies related to prostate cancer and breast cancer.

For research use only. We do not sell to patients.

Purity: 99.74%
CAS No.: 59122-93-9
Formula: C₂₁H₂₂O₉
Molecular Weight:418.39

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Neoisoliquiritin Chemical Structure

CAS No.: 59122-93-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All HSP Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HT-22	EC₅₀	72 μM Compound: 21	Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay	[PMID: 32991171]

In Vitro

Neoisoliquiritin (24-72 h) potently inhibits the proliferation of human prostate cancer cell line LNCaP with an IC₅₀ value of 19.35 μM, but exerts no effect on human prostate cancer cell line PC3^[1].
Neoisoliquiritin (20-40 μM; 5 days) reduces the viability of human prostate cancer cell line LNCaP in a dose-dependent manner following 5 days of treatment^[1].
Neoisoliquiritin (20-40 μM; 24-48 h) induces G₀/G₁ cell cycle arrest in human prostate cancer LNCaP cells by reducing the protein levels of cyclin D1 and CDK4^[1].
Neoisoliquiritin (20 μM) regulates gene expression in human prostate cancer LNCaP cells, in which the androgen receptor (AR) signaling pathway serves as its key target pathway, and downregulates genes associated with cell proliferation and cell cycle progression^[1].
Neoisoliquiritin (20 μM; 6-36 h) downregulates AR and its downstream target PSA at both mRNA and protein levels in LNCaP human prostate cancer cells^[1].
Neoisoliquiritin (20 μM; 1-24 h) blocks DHT-induced nuclear translocation of AR in human prostate cancer LNCaP cells, and inhibits DHT-induced recruitment of AR to the androgen response element (ARE) in the PSA promoter of human prostate cancer LNCaP cells^[1].
Neoisoliquiritin (10-80 μM; 24 h) inhibits the transcriptional activity of AR in AD293 cells in a dose-dependent manner (detected via PSA promoter luciferase activity), and this effect is observed after 24 h of treatment regardless of the presence or absence of DHT^[1].
Neoisoliquiritigenin (20-160 μM; 48 h) inhibits the proliferation of MCF-7 and MDA-MB-231 breast cancer cells in a dose-dependent manner, reducing cell viability to approximately 10% at the highest tested concentration^[2].
Neoisoliquiritigenin (20-160 μM) induces apoptosis in MCF-7 and MDA-MB-231 breast cancer cells, with a stronger effect on MDA-MB-231 cells^[2].
Neoisoliquiritigenin (20-160 μM) inhibits the ATPase activity of GRP78 in a dose-dependent manner, reducing the activity to approximately 50% of that in the control group at concentrations of 80 μM and 160 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

LNCaP (AR-dependent human prostate cancer)
Concentration:

20, 40 μM
Incubation Time:

5 days
Result:

Reduced LNCaP cell viability in a dose-dependent manner, with 20 μM and 40 μM treatments leading to significant decreases in viable cell counts relative to controls.

Cell Cycle Analysis^[1]

Cell Line:

LNCaP (AR-dependent human prostate cancer)
Concentration:

20, 40 μM
Incubation Time:

24 h, 48 h
Result:

Increased the LNCaP cell population in the G0/G1 phase in a time-dependent manner, with concomitant decreases in S and G2/M phase populations.
Decreased cyclin D1 and CDK4 protein levels in dose- and time-dependent manners.
Did not induce statistically significant apoptosis in LNCaP cells after 24 h or 48 h of treatment.

Real Time qPCR^[1]

Cell Line:

LNCaP (AR-dependent human prostate cancer)
Concentration:

20 μM
Incubation Time:

6 h, 12 h, 24 h, 36 h
Result:

Significantly downregulated AR mRNA levels in LNCaP cells at 24 h and 36 h, and downregulated AR protein levels relative to controls.
Significantly downregulated PSA mRNA levels at 12 h (0.5-fold), 24 h (0.3-fold), and 36 h (0.1-fold), and reduced secreted and cytoplasmic PSA protein levels relative to controls.

Immunofluorescence^[1]

Cell Line:

LNCaP (AR-dependent human prostate cancer)
Concentration:

20 μM (in combination with 10 nM DHT)
Incubation Time:

1 h
Result:

Blocked DHT-induced nuclear accumulation of AR in LNCaP cells, where DHT treatment alone induced significant nuclear accumulation of AR, and AR was mainly localized to the cytoplasm in the absence of DHT.

Cell Proliferation Assay^[2]

Cell Line:

MCF-7, MDA-MB-231 breast cancer cells
Concentration:

20 μM, 40 μM, 80 μM, 160 μM
Incubation Time:

48 h
Result:

Reduced MCF-7 cell survival to ~60% at 20 μM, ~40% at 40 μM, ~20% at 80 μM, and ~20% at 160 μM.
Reduced MDA-MB-231 cell survival to ~60% at 20 μM, ~40% at 40 μM, ~20% at 80 μM, and ~10% at 160 μM.
Inhibited cell survival in a dose-dependent manner with all reductions statistically significant relative to mock-treated cells.

In Vivo

Neoisoliquiritin (1 mg/kg; i.p.; every other day; for 45 consecutive days) exerts potent tumor-suppressive activity in AR-dependent prostate cancer xenograft mouse models, reduces tumor volume, AR expression levels and cell proliferation capacity, and does not induce hepatotoxicity or nephrotoxicity^[1].
Neoisoliquiritigenin (25 mg/kg; i.p.; once daily; for 28 consecutive days) significantly reduces the weight of breast cancer xenografts by approximately 44.7% in MDA-MB-231 mouse models and by approximately 54.1% in MCF-7-GRP78 models^[2].
Neoisoliquiritigenin (25 mg/kg; i.p.; once daily; for 8 weeks) significantly inhibits breast cancer lung metastasis by approximately 60% in the MCF-7-GRP78 mouse model, and by approximately 62.5% in the MDA-MB-231 model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

SCID mice (male, 4-6 weeks old, subcutaneous xenograft model via LNCaP cell injection)^[1]
Dosage:

1 mg/kg
Administration:

i.p.; every other day; 45 days
Result:

Significantly reduced xenograft tumor volumes compared to vehicle control, with volumes lower than those in the enzalutamide group.
Significantly reduced the percentage of AR-positive cells and Ki67-positive cells in tumor tissue compared to vehicle control.
Showed no typical pathological changes in kidney and liver tissue via hematoxylin and eosin staining, indicating no nephrotoxicity or hepatotoxicity.

Animal Model:

Nude mice^[2]
Dosage:

25 mg/kg
Administration:

i.p.; daily; 28 days
Result:

Reduced mean tumor weight from ~3.8 g to ~2.1 g in MDA-MB-231 xenografts.
Reduced mean tumor weight from ~3.7 g to ~1.7 g in MCF-7-GRP78 xenografts.

Animal Model:

Nude mice^[2]
Dosage:

25 mg/kg
Administration:

i.p.; daily; 8 weeks
Result:

Reduced mean lung metastatic nodule count from ~5 to ~2 in MCF-7-GRP78 models.
Reduced mean lung metastatic nodule count from ~8 to ~3 in MDA-MB-231 models.

Chemical Information

CAS No. 59122-93-9
Appearance Solid
Molecular Weight 418.39
Formula C₂₁H₂₂O₉
Color Light yellow to yellow
SMILES

O=C(C1=CC=C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)C=C1O)/C=C/C3=CC=C(O)C=C3
Synonyms

Neoisoliquiritigenin
Structure Classification
- Flavonoids
- Chalcones
- Phenols
- Polyphenols
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 66.67 mg/mL (159.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3901 mL

11.9506 mL

23.9011 mL

5 mM

0.4780 mL

2.3901 mL

4.7802 mL

10 mM

0.2390 mL

1.1951 mL

2.3901 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chen C, et al. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2021 May;85:153514. [Content Brief]

[2]. Tang H, et al. Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer. Current cancer drug targets. 2018;18(4):390-399. [Content Brief]

[3]. Wayne C. Liao, et al. Identification of two licorice species, Glycyrrhiza uralensis and Glycyrrhiza glabra, based on separation and identification of their bioactive components. Food Chemistry 132 (2012) 2188-2193.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3901 mL	11.9506 mL	23.9011 mL	59.7529 mL
	5 mM	0.4780 mL	2.3901 mL	4.7802 mL	11.9506 mL
	10 mM	0.2390 mL	1.1951 mL	2.3901 mL	5.9753 mL
	15 mM	0.1593 mL	0.7967 mL	1.5934 mL	3.9835 mL
	20 mM	0.1195 mL	0.5975 mL	1.1951 mL	2.9876 mL
	25 mM	0.0956 mL	0.4780 mL	0.9560 mL	2.3901 mL
	30 mM	0.0797 mL	0.3984 mL	0.7967 mL	1.9918 mL
	40 mM	0.0598 mL	0.2988 mL	0.5975 mL	1.4938 mL
	50 mM	0.0478 mL	0.2390 mL	0.4780 mL	1.1951 mL
	60 mM	0.0398 mL	0.1992 mL	0.3984 mL	0.9959 mL
	80 mM	0.0299 mL	0.1494 mL	0.2988 mL	0.7469 mL
	100 mM	0.0239 mL	0.1195 mL	0.2390 mL	0.5975 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Neoisoliquiritin

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Glycoside Compound Library

Medicine Food Homology Compound Library

Phenols Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Tibetan Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

All HSP Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Neoisoliquiritin Related Classifications

HY-N2122 Related Classifications